1 Department of Medicine.
2 Department of Community Health Sciences, and.
Ann Am Thorac Soc. 2017 Sep;14(9):1373-1377. doi: 10.1513/AnnalsATS.201702-137OI.
Interstitial lung disease (ILD) comprises a large and heterogeneous group of disorders that often lead to progressive fibrosis and premature death. Oxygen supplementation is typically used in patients with advanced lung disease with resting hypoxemia; however, there is a paucity of evidence guiding the use of supplemental oxygen in ILD, and significant heterogeneity in clinical practice. It remains unclear whether supplemental oxygen improves clinically meaningful outcomes, and the role of ambulatory oxygen supplementation in isolated exertional hypoxemia is particularly controversial. In some regions, the lack of robust data creates barriers to funding support and access to supplemental oxygen for patients with ILD. Further research into the role of oxygen supplementation is needed to optimize the comprehensive care of this patient population.
间质性肺疾病（ILD）包含一大组异质性疾病，这些疾病通常导致进行性纤维化和过早死亡。对于静息性低氧血症的晚期肺病患者，通常会使用氧气补充治疗；然而，ILD 患者使用补充氧气的指导证据有限，且临床实践中存在很大的异质性。补充氧气是否能改善有临床意义的结局尚不清楚，在孤立性运动性低氧血症中使用日间补充氧气的作用尤其存在争议。在一些地区，由于缺乏强有力的数据，导致为ILD 患者提供补充氧气的资金支持和获取受到阻碍。需要进一步研究氧气补充治疗的作用，以优化该患者人群的综合护理。
